SHP.L - Shire plc

LSE - LSE Delayed Price. Currency in GBp
4,626.00
-76.50 (-1.63%)
At close: 4:37PM GMT
Stock chart is not supported by your current browser
Previous Close4,702.50
Open4,698.50
Bid4,320.00 x 51000
Ask4,650.00 x 53800
Day's Range4,626.00 - 4,715.50
52 Week Range2,940.50 - 4,780.00
Volume2,869,415
Avg. Volume2,598,434
Market Cap42.025B
Beta (3Y Monthly)0.96
PE Ratio (TTM)8.81
EPS (TTM)524.80
Earnings DateFeb 11, 2019 - Feb 15, 2019
Forward Dividend & Yield0.26 (0.56%)
Ex-Dividend Date2018-09-06
1y Target Est63.41
  • GlobeNewswire10 hours ago

    U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide ) for Children with Short Bowel Syndrome

    Intended for U.S. Audience U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide ) for Children with Short Bowel.

  • Reutersyesterday

    Takeda's Shire takeover to bring $963 million fee bonanza

    Banks, law firms and other advisers stand to earn up to $963 million (£749.3 million) in fees from Takeda Pharmaceutical's $62 billion (48.3 billion pounds) takeover of drugmaker Shire (SHP.L), according to documents for the deal published on Monday. The deal will be the largest-ever overseas acquisition by a Japanese company and will lead to big payments to advisers working on both sides of the transaction. The Japanese company expects spend about $733.4 million in fees and expenses in total, while London-listed Shire's costs will range between $216.5 million and $229.5 million, the companies disclosed in the documents.

  • Reuters2 days ago

    Takeda sets vote date, aims to close $62 billion Shire deal Jan. 8

    Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire (SHP.L) next month and aims to close the deal on Jan. 8, signaling its confidence in securing the required support. Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March. Takeda said on Monday it would hold an extraordinary general meeting (EGM) of shareholders to vote on the transaction on Dec. 5.

  • Reuters2 days ago

    Takeda sets vote date, aims to close $62 billion Shire deal on January 8

    Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion (47.92 billion pounds) acquisition of Shire (SHP.L) next month and aims to close the deal on Jan. 8, signalling its confidence in securing the required support. Shares in London-listed Shire rose 3 percent on the news, hitting their highest level since Takeda first disclosed its interest in buying the rare diseases specialist in March. The deal would be the biggest-ever overseas acquisition by a Japanese company - but it needs two-thirds support from shareholders, some of whom are worried about the enlarged company's resulting debt burden.

  • Financial Times2 days ago

    [$$] Takeda sets date for shareholder vote on £46bn Shire deal

    The key vote comes as a group of shareholders, including several founding family members of Takeda, steps up a campaign to derail a deal that Japan’s largest drugmaker sees as critical to catapulting itself into the ranks of the world’s biggest pharmaceutical companies. “With the date of our extraordinary general meeting of shareholders now set, we are looking forward to continue our dialogue with shareholders regarding the compelling strategic and financial benefits of this transaction,” Christophe Weber, the chief executive of Takeda, said in a statement. Takeda, which initially said it would hold the vote in early 2019, has brought the date forward as management has become increasingly confident about the prospects of the company securing a two-thirds approval from shareholders to issue new shares to finance the acquisition.

  • GlobeNewswire2 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire2 days ago

    Publication of Scheme Document

    Shire is pleased to announce that the scheme document which sets out, among other things, a letter from the Chairman of Shire, the full terms and conditions of the Scheme, an explanatory statement, notices of the Court Meeting and the Shire General Meeting, an expected timetable of principal events and details of the action to be taken by Shire Shareholders and Shire ADS Holders, is being sent, or made available, to Shire Shareholders and Shire ADS Holders today and has been published on the Shire website at www.shire.com (the “Scheme Document”). Together with the Scheme Document, Forms of Proxy for the Court Meeting and the Shire General Meeting and Forms of Election and the notes accompanying them have also been published on the Shire website at www.shire.com. A Notice of Court Meeting and Extraordinary General Meeting, together with an ADS Voting Card, is also being sent to Shire ADS Holders today by the Shire Depositary.

  • Financial Times2 days ago

    [$$] Takeda and Shire to pay almost $1bn in deal fees and expenses

    Drugmakers Takeda and Shire  are set to pay almost $1bn in expenses and fees to advisers, an enormous payday for the banks and law firms working on Japan’s largest overseas corporate takeover. Bankers ...

  • Reuters4 days ago

    Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources

    Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its $62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday. Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio. Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.

  • Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
    Zacks4 days ago

    Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3

    Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.

  • GlobeNewswire5 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Moody's5 days ago

    Takeda Pharmaceutical Company Limited -- Moody's assigns A2 to Takeda's proposed notes; places rating under review for downgrade

    Moody's Japan K.K. has assigned A2 ratings to Takeda Pharmaceutical Company Limited's (A2 review for downgrade) proposed senior unsecured notes. These new notes are under review for downgrade as are Takeda's ...

  • Takeda Hires Banks for Euro Bonds to Finance Shire Takeover
    Bloomberg5 days ago

    Takeda Hires Banks for Euro Bonds to Finance Shire Takeover

    (Bloomberg) -- Takeda Pharmaceutical Co. Ltd has picked banks to arrange a euro bond offering to finance its $62 billion acquisition of larger rival Shire Plc.

  • The Wall Street Journal6 days ago

    [$$] Shire Spinout Mirum Pharmaceuticals Launches With $120 Million

    Some drug companies are parting with compounds they can’t afford to develop or that are no longer a priority. Several startups have gathered these assets, which have often been tested in clinical trials. Mirum secured a drug that is set for Phase III studies.

  • GlobeNewswire7 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of SHP.L earnings conference call or presentation 1-Nov-18 2:00pm GMT

    Q3 2018 Shire PLC Earnings Call

  • GlobeNewswire8 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Reuters8 days ago

    Takeda CEO confident of investor backing for $62 billion Shire deal

    The boss of Japan's Takeda Pharmaceutical said on Monday he was confident of securing investor backing for its $62 billion acquisition of London-listed Shire, despite some shareholders' fears about the resulting debt burden. Buoyed by a strong set of quarterly results last week - helped by strong demand for its existing drugs - Chief Executive Christophe Weber insisted that buying rare diseases specialist Shire was not a defensive move. "We are quite satisfied with our current progress at Takeda.

  • Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3
    Zacks11 days ago

    Shire's (SHPG) Earnings, Revenues Miss Estimates in Q3

    Shire (SHPG) misses earnings and revenue estimates in the third quarter of 2018. The company completes the sale of its Oncology franchise in the quarter.

  • GlobeNewswire12 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Associated Press12 days ago

    Shire: 3Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had net income of $1.75. Earnings, adjusted for non-recurring costs, came to $3.64 per share. The results fell short of Wall Street expectations. ...

  • The Wall Street Journal12 days ago

    [$$] Shire 3Q Net Profit Falls on Taxes

    Shire said that net profit fell 2.5% in the third quarter on higher tax expenses as well as reorganization costs.

  • GlobeNewswire12 days ago

    3rd Quarter Results

    Shire Delivers Product Sales Growth of 6% and Continues to Execute Against Key Priorities in Q3 2018   Delivered product sales of $3.8 billion; growth driven by Immunology,.

  • GlobeNewswire13 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire13 days ago

    Form 8 (DD) - Flemming Ornskov

    FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)Rules 8.1, 8.2.